Prophylaxis of experimental bone marrow transplant nephropathy

Area of Science:

• Nephrology
• Radiation Oncology
• Pharmacology

Background:

• Renal radiation injury is a significant complication following local kidney irradiation and total body irradiation (TBI).
• Chronic renal failure after bone marrow transplantation (BMT) is linked to TBI.
• Understanding TBI's impact on renal function is crucial for patient outcomes.

Purpose of the Study:

• To investigate the protective effects of ACE inhibitors (enalapril, captopril) and verapamil against radiation nephropathy.
• To evaluate the efficacy of these drugs in mitigating proteinuria, azotemia, hypertension, and improving survival post-TBI/BMT.
• To determine the dose-dependent effects of captopril on radiation-induced renal injury.

Main Methods:

• 211 WAG/Rij/MCW rats received 0-20 Gy TBI followed by syngeneic BMT.
• Animals were treated with verapamil, enalapril, or captopril in drinking water starting 9 days pre-TBI.
• Outcomes including proteinuria, azotemia, blood pressure, and survival were monitored up to 55 weeks.

Main Results:

• Untreated irradiated rats developed significant proteinuria, azotemia, and hypertension.
• Captopril demonstrated a dose-dependent reduction in proteinuria, blood pressure, and azotemia, enhancing survival.
• Captopril (500 mg/L) outperformed enalapril (50 mg/L) in all measured parameters; verapamil showed no benefit.

Conclusions:

• Angiotensin-converting enzyme inhibitors are beneficial in preventing radiation nephropathy.
• Controlling proteinuria is critical for preventing the progression of renal failure following TBI.
• ACE inhibitors represent a promising therapeutic strategy for mitigating radiation-induced kidney damage.